According to industry and congressional sources, a deal on intellectual property rights for biologic drugs under the TPP may be in the near future. According to recent comments from U.S. Trade Representative Michael Froman, biologics is the last major issue that needed to be addressed.

Read the full article on Bloomberglaw.com. (Subscription required)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.